Home Blog Page 100

One in Four Canadians Report not Having Taken Medication Properly

0

 

A national survey conducted in January by Pharmasave – Canada’s leading community pharmacy – shows that 26 percent of the more than 10,000 respondents admit to having taken medication differently than prescribed or stopping to take it without consulting their doctor or pharmacist.

In response to the survey results, Pharmasave has launched a public education campaign to raise awareness of the dangers of not taking medication as directed.

“The number of Canadians not adhering to medication is concerning and brings with it potentially serious consequences, especially for those with chronic conditions,” said Jaspreet Chager, Senior Manager, Pharmacy Innovation with Pharmasave. “This can include worsening medical conditions, complications and increased hospitalizations, which is especially concerning at a time when our health care system is already burdened with the pandemic.”

Even before COVID-19, the World Health Organization (WHO) declared that the rise of chronic illnesses such as diabetes, heart disease, chronic respiratory diseases and cancer was a “slow-motion” disaster contributing to about 70 percent of deaths globally. “Heading into the third wave of the pandemic, there’s concern about the disruption in usual chronic care treatment, so it’s more important than ever to be adherent with medications,” Chager said.

Of those surveyed, only 14 percent said they have been more diligent with taking their prescribed medications during the pandemic. Top reasons cited include wanting to be in top health since they are at greater risk if they contract COVID-19 due to a pre-existing condition (62 percent) and finding it easier to remember to take their medication since they are always at home (40 percent).

For respondents who reported not having taken their long-term medication properly, 38 percent said they occasionally forgot to take doses of their medication, while 21 percent forgot to take the medication altogether. Others indicated the medicine made them feel sick (24 percent) or were too expensive (11 percent), or that they felt better, so didn’t see the need to continue (14 percent).

Almost a quarter of those surveyed admitted to not having filled or refilled their prescription at some point, reasoning that the medicine was too expensive or not covered by their drug plan or insurance (38 percent), that they didn’t think it was necessary (33 percent), or that they were afraid of side effects (22 percent).

What can help ensure better adherence to prescriptions, regardless of the pandemic? Pharmasave offers these tips:

Rely on smart packaging. Ask your pharmacist to blister pack your medications for you. Blister packs are pre-made bubble packs with designated sealed compartments that sort medications by day or time of day, such as morning, noon, afternoon, and bedtime. You can also use dosettes, small containers with a window for each day or time of day. Both of these handy packages make it easy to tell which medications should be taken at what times, and let you keep track of your doses.

Use reminders. The alarm on your watch, mobile device, cell phone or clock can alert you when it’s time for your next dose. Many pharmacies, including Pharmasave, also have mobile apps you can use to set reminders, and some offer reminder services by phone or email. Keeping track of your doses on a chart or calendar can do the trick as well.

Keep it simple. If you’re taking pills more than once a day, talk to your pharmacist about a medication review. Explore if there’s a treatment you can use only once a day or see if you can switch to a combination product containing both medications in a single pill. Studies show it’s easier to remember your medication if you take it once a day rather than more frequently.  

Make it a habit. Take their medication at the same time as something else you do regularly, such as brushing your teeth in the morning or at night. Before you choose an activity, check with your pharmacist or doctor to see if your medication should be taken with or without food and whether it’s better taken at a certain time of day.
Speak to your pharmacist. As frontline healthcare professionals who specialize in medication, set up an appointment with your pharmacist – by phone, video or in-person – to review your prescriptions and come up with an adherence plan that’s best suited to your needs and lifestyle. Pharmasave, for example, has a MedAlign program that makes it easier for people to stick with their medications by synchronizing their prescriptions to be refilled on the same day, provide blister packaging to ensure no doses are missed and set medication reviews and reminders. Pharmacists can also suggest ways to minimize side effects and reduce costs of medication.

“In spite of the pandemic, pharmacies have made access to medication as easy as possible, including home deliveries and curbside pick-up – another step in pharmacists’ efforts to help people take their medications properly,” Chager said.

GreenSpace Announces Private Placement

0

 

The company has engaged a syndicate of agents led by Canaccord Genuity Corp. (collectively, the “Agents“) on a commercially reasonable best-efforts basis in connection with a proposed brokered private placement (“Offering“). The Offering will consist of units (the “Units“) of the Company to raise gross proceeds of up to $3,000,000 and the Agents have an option to increase the size of the Offering by up to 15% at any time prior to the closing of the Offering.  The issue price per Unit will be determined in the context of the market.

Each Unit will consist of one common share in the capital of the Company (“Common Share“) and one-half of one common share purchase warrant (each whole warrant, a “Warrant“).  Each Warrant which will entitle the holder of the Warrant to purchase one Common Share at a price  to be determined in the context of the market (“Exercise Price“) for up to 24 months from the date of closing (“Expiry Date“), provided that if at any time between the date that is four months and one day from the closing of the Offering and the Expiry Date, the daily volume weighted average closing price of the Common Shares on the TSX Venture Exchange is greater than an amount to be determined in the context of the market for ten consecutive days, the Company shall have the option to accelerate the expiry of the Warrants by delivering notice to holders of the Warrants (the “Acceleration Notice“).  In such instances, the Warrants will be exercisable only until the 30th day following delivery of the Acceleration Notice.

The net proceeds of the Offering will be used for working capital and general corporate purposes.

PenderFund Capital Management Ltd., an insider and control person of the Company (“PenderFund“), will subscribe for 20% of the Units under the Offering.  PenderFund and its affiliates currently own Common Shares, representing 36.3% of the issued and outstanding Common Shares (not including the Warrants acquired as part of the private placement which closed on December 23, 2020).

In Connection with the Offering, the Agents are to receive as compensation: (i) a cash commission of 7% of the gross proceeds raised pursuant to the Offering; and (ii) a non-transferable broker warrants entitling the Agents to acquire in aggregate that number of Common Shares which is equal to 7% of the number of Units issued under the Offering, which broker warrants will have an exercise price at which the Units are priced under the Offering and a term of eighteen months from the closing of the Offering, subject to reduction to 3% in each case for certain agreed subscribers (collectively, the “Agents’ Fee“).

Closing of the Offering is expected to occur on March 31, 2021, or such other date as agreed upon by the Company and Agents, and is subject to receipt of all necessary corporate and regulatory approvals, including the approval of the TSX Venture Exchange (“TSXV“). The Units and the securities issued thereunder will be subject to a statutory hold period of four months plus a day from the closing date in accordance with applicable securities legislation.

Costco Opens 3rd Canadian ‘Business Centre’ Storefront

0

 

The new Business Centre, in Gloucester, Ontario, is the third Canadian center for the company since the concept was launched in Scarborough, Ontario in March 2017 with a second location that opened fall 2020 in Saint-Hubert, Quebec.

“We are thrilled to open our doors and offer this new service, which will better respond to the needs of local business owners,” said Marc-André Bally, Vice President of Business Centres and Ancillary Businesses, Costco Wholesale Canada.

The Costco Business Centre concept is already a resounding success in the Toronto area, and we look forward to offering the same benefits to businesses in the Ottawa/Gatineau region, which we also hope will bring many new consumers to discover the benefits of a Costco membership.”

Bally said the Business Centre is a division that caters primarily to business owners. Although it is open to all Costco members, he said, the Business Centre concept is vastly different from the traditional Costco warehouse, with more than 70 percent of the product offerings unique to the Business Centre and targeted to meet the needs of businesses of all sizes.

“Those products are unique to this Business Centre. You’re going to find that there’s some categories that we’re not selling like TV sets and apparel to name a few but we compensate with a much deeper offering in beverages, in candy, in kitchen appliances, commercial appliances and accessories as well as an 11,000-square-foot walk-in cooler where you can walk and shop at the same time with your cart,” said Bally.

The Business Centres are standalone buildings and separate locations from a traditional Costco store.

“We also have a website that business owners can choose to have their products delivered. We operate a fleet of trucks with our own trucks, our own Costco drivers. If you go on our website, we’ll deliver the goods to your place of business on the next business day,” said Bally.

“We are opening two more in April. We are opening in Edmonton and in St. Catharines, Ontario.”

The Gloucester center:1900 Cyrville Road, 123,000 sf.

The annual fee is $60 for a Business Membership or $60 for a Gold Star Membership. All Costco Wholesale memberships include a free Household card and are valid at all Costco locations around the world.

At an annual fee of $120 per year, Costco also offers an enhanced Executive Membership that includes a two percent reward (up to $1,000 annually) on all qualifying Costco purchases and a free Household Card.  Those who choose the Executive Membership option receive exclusive merchandise offers, as well as special incentives on Payment Processing, Travel Insurance, Portable and Self-storage, and more.

Source: Retail insider

Shoppers Drug Mart marks historic COVID milestone with first vaccine in pharmacy

0
Shoppers Drug Mart Associate Owner Tony Alm gives the store's first COVID-19 vaccine to Eugene Bochon in Edmonton, AB. (CNW Group/Loblaw Companies Limited)

 

Shoppers Drug Mart and Loblaw pharmacies in Real Canadian Superstore locations in Alberta delivered the first COVID-19 vaccines in community pharmacies, marking a milestone in the ongoing efforts to stop the spread of COVID-19.  Pharmacies throughout Alberta started administering the Pfizer vaccine to residents over the age of 75.

“Pharmacists are among the most trusted healthcare professionals, providing convenient and accessible community-level health services,” said Jeff Leger, President, Shoppers Drug Mart. “Across Canada, there are more than 10,000 pharmacies, in rural areas and urban centres. Based on the most recent flu season, it is expected that community pharmacies could vaccinate up to 3 million Canadians each week.”

Vaccines are available today in Alberta at more than 40 Loblaw-owned pharmacies, with more pharmacies expecting shipments in the coming week.

Cognetivity Neurosciences Announces Commercial Deployment of OptiMind Wellness App with Market-Leading Telehealth Company

0

 

Cognetivity Neurosciences Ltd. announced that it has reached an agreement with Dutch telehealth company Luscii healthtech BV (“Luscii”) regarding the deployment of Cognetivity’s wellness app, OptiMind. Luscii will deploy OptiMind’s sophisticated cognitive measurement capabilities in order to better understand the impact of its innovative human resources policies and corporate wellness initiatives.

Luscii is a provider of remote monitoring services for patients with conditions ranging from cancer and diabetes to Covid-19. It is the Dutch market leader, deployed in over half of hospitals in the Netherlands, and is now active in several other countries, including the UK. This success has been underpinned by innovation, both in its products and services and in its approach to employee welfare. As Luscii rolls out a major new wellness initiative within the business, it will deploy OptiMind to give better personal insights to team members and improve its understanding, via aggregate data, of the overall impact of its investment.

“Luscii supports many thousands of patients and clinicians through remote monitoring.” said Professor Daan Dohmen, Chief Executive of Luscii. “Anything I can do to help improve the working environment for my colleagues will help them and, in turn, help patients and clinicians too,” he said. “Learning what works in this context has been challenging until now, but Cognetivity’s incredible technology opens up new and exciting possibilities for measuring the real impact of targeted programs and I look forward immensely to learning from the insights OptiMind will deliver.”

Employee wellbeing continues to assume growing importance in the business world, with the global corporate wellbeing market forecast to expand from US$53.6 billion in 2018 to US$90.7 billion by 2026. Large employers in the US spent an average of $762 per employee on wellbeing programs in 2019. However, the return on such investments remains unclear, with firms unable to quantify program impact at either an individual or organizational level.

Meanwhile, consumers remain increasingly keen to use technology to track aspects of their physical health, such as activity levels, weight and heart rate – but the prospect of day-to-day measurement of brain performance, particularly in relation to core lifestyle factors such as sleep, exercise and diet, has remained elusive. On top of all this, the pandemic has disrupted working norms. Many people are working from home and therefore unable to access the formal and informal support networks and wellbeing initiatives ordinarily available in the office environment.

OptiMind sits at the confluence of these major global trends. It is a wellness app, created for easy use by consumers, that is nevertheless supported by the same medical-grade cognitive assessment functionality that powers Cognetivity’s flagship clinical product, the ICA. Geared towards the personalized tracking and management of cognitive performance, it is also designed to enable feedback loops between employees and employers for the monitoring of wellbeing and risk. Optimind is also designed with enterprise scale in mind, being capable of serving the needs of millions of concurrent users around the world.

“Many progressive employers have strived to increase the impact of mental wellbeing efforts in the workplace to better support their employees and improve efficiency,” explained Dr Sina Habibi, Cognetivity’s CEO. “Crucially, OptiMind makes it practical and cost-effective to measure the impact of these initiatives. With OptiMind based on the same underlying science and technology that underpins our clinical products, and therefore benefiting from not only clinical validation but also speed and ease of use, our fundamentally different approach to cognitive testing is now opening an entirely new way for companies to support their staff. This is very much the future of working and looking after employees in and out of the workplace, using tools like ours to proactively look after health and improve productivity and safety.”

“The work that Luscii is doing in this area is enormously exciting and we are honoured to be able to contribute to it,” he added. “There has never been a more important time to look after your employees, and there has never been a tool quite like OptiMind to help you to do so.”

The Company also granted 80,000 stock options to employees of the Company exercisable at a price of $0.84 per common share for a period of 5 years from the date of grant.

Clinical Review: Effects and Presumed Mechanism of Action of the French Oak Wood Extract Robuvit

0

 

Introduction

Not many plants can provide mankind with food and shelter. Big enough to construct houses, strong enough to build boats resisting ocean travels, and energy-packed to warm up cold winter nights since centuries, the oak tree has historically intermingled with several fundamental aspects of human life. Since antiquity, the oak tree has also granted a more discrete, but direct contribution to human diet. Archetypal European beverages such as wine, sherry, spirits, brandy, whisky, or condiments such as vinegar share oak as the favorite wood type for the barrels, they are slowly matured in a traditional process, which can last up to several decades. During aging, various soluble oak components diffuse into the liquid and, among other properties, enhance the intensity and complexity of its flavors.1–3 Another such property is the longer storage life resulting for wines and
spirits. This is presumably the primary reason for the practice of aging beverages in oak wood containers. The use for food, such as miso, soy sauce, kimchi, and sauerkraut, attests a protection from spoilage conferred, in part, by the extractables obtained from oak wood containers. Among the different oak species, one is especially praised among winemakers as yielding the highest quality wines: French oak (Quercus robur L.).4 Conveying benefits of this esteemed oak to humans led to the introduction of Robuvit
standardized French oak wood extract to the market in 2014, manufactured by Horphag Research. To structure and summarize the numerous health benefits of this dietary
supplement, evidenced by clinical trials,5–28 is the main topic of this review. Its composition, bioavailability, and safety aspects will also be discussed, along with plausible mechanisms of action.

Composition

The botanical species used to manufacture Robuvit is Q. robur L. (Linnaeus). It belongs to the Fagacea family, genus Quercus, and is collected in the Massif Central region in France from forests controlled by French agricultural and forestry authorities. This ensures sustainability and respect of stringent environmental protection guidelines.

Once gathered, the wood plant part (lignum) is extracted using water as the sole solvent. The resulting organoleptic features of Robuvit are a soft characteristic odor and a taste
in the woody family notes, more specifically humic, tannic, underwood, and a light beige fine powder appearance. Robuvit is standardized to contain no less than 40% polyphenols,
as measured by the well-established Folin–Ciocalteau total phenolic assay.29 Its polyphenols belong to the ellagitannin class, named after the ellagic acid moiety esterifying
every individual of this class. It possesses potent antioxidant and free-radical scavenging properties.30 The ellagitannins determined in Robuvit are the diastereoisomers castalagin
and vescalagin (a-hydroxyl aglycone and b-hydroxyl aglycone, respectively), along with grandinin and roburin E.

These compounds differ in their glycosylation patterns (bxylose and b-lyxose) (Fig. 1A). The dimeric versions of these structures and signature bioflavonoids specific for Q. robur are roburins A, B, C, and D, also differing in their glycosylation patterns (a-hydroxyl aglycone, b-lyxose, bxylose, and b-hydroxyl aglycone) (Fig. 1B).9 Other compounds such as castalin, vescalin, and smaller phenolic acids (ellagic acid and gallic acid) are also found in Robuvit.9

Metabolism and Bioavailability

After initial in vitro reports suggested antiatherogenic, antithrombotic, anti-inflammatory, and antiangiogenic effects of ellagitannins, the in vivo metabolites of ellagitannins were established to be beneficial in the context of cardiovascular health.31 The metabolism of dietary ellagitannins is now known to proceed from ellagic acid through decomposition
by gut bacteria into the bioactive metabolites urolithin A, B, and C.32 At least one bacterial species present in the human gut microflora specifically involved in this reaction was identified.33 Urolithins A, B, and C refer to the 3-mono-, 3,8-di-, and 3,8,9-tri-hydroxyurolithins, respectively, depicted in Figure 2.

Robuvit administered three times daily (3 · 100 mg) over a period of 5 days to healthy volunteers was found to significantly increase plasma polyphenols by twofold, coinciding with significant increase in plasma antioxidant capacity.9 The volunteers abstained from flavonoid consumption during this time, especially chocolate, fruits, tea, and wine, as much as feasible.9 Daily ingestion of Robuvit for 5 days led to the identification of oak roburin metabolites urolithins A, B, and C as well as ellagic acid as glucuronides or diglucuronides.9 Furthermore, bioactivity was also demonstrated through an increase of the antioxidant capacity and specific changes of gene expression profile, affecting ribosome, cell cycle, and spliceosome pathways.9 In a randomized, double-blind, controlled clinical study, the effect
of Robuvit supplementation on patients undergoing hysterectomy was investigated.5 Interestingly, the urolithin levels in patients consistently increased over 8 weeks of Robuvit
supplementation, which suggests that a chronic intake of Robuvit can induce or amplify the gut bacteria responsible for the urolithin production, leading to an increase in the number of urolithin producers (Fig. 3).5

Safety

Humans have been exposed to oak wood extracts for as long as they have been storing alcoholic beverages and food in oak barrels—that is several millennia in Europe. The safety of Robuvit oak wood extract was tested using the broad array of toxicology studies.34 All tests performed concluded that Robuvit is neither genotoxic nor mutagenic.

Dermal toxicity tests also revealed that Robuvit is neither irritant nor corrosive and is not a sensitizer. Regarding oral intake, acute and chronic toxicity concluded that a dosage of >700 mg/day is safe, considering European Food Safety Authority guidelines.35 Based on this excellent safety profile, Robuvit has also been granted self-affirmed Generally Recognized as Safe status for the United States in 2017 for use in conventional food, by an independent panel of toxicology experts. Published clinical studies used various dosages (up to 600 mg/day) and durations (up to 6 months), depending on the application.5–28 To date, a total of 549 patients took Robuvit in medically supervised studies, and no adverse effects have been reported during any of the studies carried out.

Mechanism of Action

Robuvit affects cellular mitochondria and ribosomes, improving energy and (muscle) protein synthesis and in addition, it decreases oxidative stress (Fig. 4).9,13,36,37 Mitochondria regeneration Ingested Robuvit polyphenols undergo metabolism by gut microbiota, which generates urolithins A, B, and C (Fig. 1).9 The Robuvit metabolite urolithin A favorably affects mitochondria for enhanced energy production in a process referred to as mitophagy.36,38 Dysfunctional mitochondria are removed through autophagy, and the turnover of mitochondria is promoted, thus preserving energy metabolism.

The mitophagy process ensures that optimal energy in form of adenosine triphosphate (ATP) is gained from consumed food.36,38 Mitochondria generating ATP might be also subjected to oxidative damage, which progressively affects the ATP energy output. Mitochondrial regeneration, or mitophagy, is accelerated in presence of Robuvit supplementation and in consequence, a higher energy output may be deployed (Fig. 4, upper right part).36,38 In addition to that, a gene expression analysis showed a significant increase in mitochondrial protein nicotinamide adenine dinucleotide (NADH)-dehydrogenase after Robuvit supplementation. This enzyme is directly involved in the electron transport of the respiratory chain to generate ATP and thus improves energy production (Fig. 4, upper left part).9

Increase in muscular mass

Another metabolite found in blood after Robuvit intake— urolithin B—was shown to be a regulator of skeletal muscle mass by inducing muscle hypertrophy (muscle growth), increasing protein synthesis, and enhancing metabolism and energy expenditure (Fig. 4, lower right part).37 Stimulated protein synthesis through urolithin B is achieved by activation of the mTORC1 signaling pathway through interaction with the androgen receptor in a nonhormonal way.37

This was shown in experiments, conducted in myotubes (multinucleated muscle cells) as well as in in vivo experiments. 37 Urolithin B further leads to the inhibition of the degradation of proteins by downregulation of the ubiquitin proteasome pathway.37 In both of these mechanistic effects, urolithin B seems to mimic the effect of testosterone, which acts in a similar way, enhancing muscular mass.37

Ribosomal biogenesis

Clinical research revealed that supplementation with Robuvit in healthy volunteers stimulates ribosomal biogenesis in response to ellagitannin metabolites (Fig. 4, lower left part).9 Volunteers’ serum samples were investigated ex vivo for gene expression modulations in three selected target tissues: endothelium, neuronal, and keratinocyte cell lines.9 The results, showing increased expression of ribosomal genes, give rise to the expectation of expanded and accelerated protein synthesis capacity since ribosomes
synthesize new proteins from mRNA templates. To date, 24 clinical trials unequivocally point to a significant increase in energy in individuals supplemented with Robuvit, in absence of stimulant effects, as neither heart rate nor blood pressure were reported to be altered.5–28 This increased energy generation efficiency is proposed to be the driving force for an enhanced endurance, performance, and faster recovery.

Increase of antioxidant capacity of blood plasma A clinical study with 20 healthy volunteers, aged 45–65 years indicated an antioxidant potential of Robuvit (Fig. 4, lower middle part).13 Supplementation with 300 mg Robuvit daily for 1 month was ascribed to significantly decrease serum levels of advanced protein oxidation products and lipid peroxides. Interestingly, the study revealed that supplementation with Robuvit significantly stimulated the presence of plasma antioxidant enzymes, such as superoxide dismutase and catalase.13 The decreased levels of oxidized proteins and lipid peroxides were found to remain significantly lowered 2 weeks past cessation of Robuvit intake.13 A double-blind, placebo-controlled study in 48 patients recovering from surgery confirmed these results.5

The patients received 300 mg Robuvit per day or placebo. The levels of oxidized proteins and lipid peroxides were significantly lowered after 4 and 8 weeks compared with placebo and baseline.5 In addition, in a study with 40 men aged 50–65 years, the oxidative stress in terms of plasma free radicals, measured in Carr units decreased by 15% compared to the control subjects upon Robuvit supplementation.24 Ribosome biogenesis can be affected by hypoxia and oxidative stress as well. Alterations of those mechanisms in ribosome biogenesis are implied in cardiovascular, neurodegenerative, and skeletal disorders.39 Since urolithins generated from Robuvit stimulate ribosome biogenesis,9 in addition to their antioxidative effects,5,13,24 Robuvit may enable an organism to better and more rapidly adjust to challenging situations. Clinical studies have illustrated the above-mentioned mechanisms of action for the compounds and metabolites of Robuvit in different human populations and health indications.

Since most of these studies were pilot studies with a limited number of participants, bigger studies with broader populations are warranted to confirm the effects of Robuvit in an array of specific health markers. Further systematic research on these oak-derived compounds is necessary to uncover the full potential of this new extract.

Clinical Effects of Robuvit

The reported improved mitochondria regeneration, enhanced ribosomal biogenesis, increased muscle mass, and the elevated antioxidant capacity caused by urolithins give a
rational basis for the results of clinical trials with Robuvit, which was shown to accelerate overall energy.8,22–24 Decreased fatigue symptoms22,23 and better sleep,16,23,27 faster
recovery after disease7,10–12,17,19,26 or surgery,5,14 improved mood,8,16,27 enhanced erectile function,22,24 reinforced antioxidant defense mechanisms in periods of stress,18 or enhanced muscle mass gain after intense exercise6 are the effects that have been described in diverse clinical studies (Fig. 5). In addition, an ameliorating effect on minimal lymphedema could be observed after supplementation with Robuvit in several studies.20,21,28 However, the mechanism of action for this effect is not yet fully elucidated. The antioxidative and anti-inflammatory action of Robuvit13,24 could have beneficial impacts in this context, as oxidative stress, enhanced formation of reactive oxygen species and accelerated lipid peroxidation processes are present in chronic lymphedematous tissue.40,41

Increase of energy and decrease of fatigue

The earliest study attributing energizing properties to Robuvit supplementation was carried out with 20 healthy individuals aged 45–65 years, neither requiring nor taking medications.8 Fatigue and energy were semiquantitative assessed with the ‘‘activation-deactivation, 12-item rating scale,’’ initially introduced by Thayer.42 Study participants refrained from flavonoid consumption, other than Robuvit, during the entire trial period. The applied questionnaire provided participant’s energy level subdivided into four categories: ‘‘energy,’’ ‘‘calmness,’’ ‘‘tiredness,’’ and ‘‘tension.’’

Four weeks supplementation with daily 300 mg Robuvit significantly improved the energy of subjects (P < .02), and conversely reduced the tiredness score of study participants (P < .02) (Fig. 6).8 Robuvit improves mood, fatigue, and insomnia. In a clinical study, 40 study participants, who presented with signs and symptoms of fatigue, insomnia, and/or mood alterations, were recruited for a study to identify improvements of symptoms over an observational period of 8 weeks.16 Mood tests resulted in a significant improvement in 13 out of 16 mood parameters, rated by the Brief Mood Introspection Scale.43 With Robuvit supplementation (300 mg daily), oxidative stress levels decreased significantly after 4 and 8 weeks, fatigue and insomnia scores were also significantly decreased compared to controls. The supplemented subjects slept 33% more and felt much fitter in the morning, being in better mood and with less fatigue during the day.16 Robuvit increases general vigor. A recent registry study included 40 men, 50–65 years old with self-reported decreased general vigor.24 The effect of 300 mg Robuvit per day on the energy status of these men was investigated.

After 4 weeks, the antonyms for vigor characteristics, such as apathy, clumsiness, powerlessness, weakness, fatigue, or initial impotence, were all significantly decreased. Properties related to vigor, such as physical and mental health, energy, force, or mental vitality, showed significant improvement. In conclusion, Robuvit supplementation was shown to improve several characteristics of dys-vigor in this study.24

Robuvit supports energy restoration in chronically fatigued individuals. Robuvit was taken by 48 individuals presenting with signs of exhaustion in chronic fatigue syndrome.
23 Improvement of symptoms was assessed using a visual analog scale. The results were compared to a group of 43 comparable subjects who did not receive a supplement. The study outcome suggests significant fatigue reduction and a more refreshing sleep after 3 months and further energy restoration after a 6-month daily supplementation with 300 mg Robuvit.23 This study further points to improved memory and better ability to concentrate. In another investigation, 38 chronically fatigued individuals were found to respond favorably to 4 weeks supplementation with 300 mg Robuvit daily compared to a matching control group of 42 participants.22 The 80 patients were suffering from fatigue since half a year and were at a stage during which taking a rest would not help to overcome exhaustion. Recruited subjects were medically diagnosed for absence of organic and psychologic disorders. Inclusion criteria utilized a questionnaire for chronic fatigue syndrome, which was further used to probe Robuvit supplementation treatment effects
after 4 weeks. Robuvit intake was ascribed to significantly alleviate signs and symptoms of fatigue, compared to a control, which did not experience significant improvement of fatigue. Robuvit increased the energy level by 48%.22

Enhanced recovery ability

Robuvit metabolites reduce fatigue and promote postsurgical recovery. A randomized, double-blind, placebocontrolled, clinical study investigated 66 female subjects who underwent hysterectomy.5,14 The group of participating women were randomly assigned to be either supplemented with 300 mg Robuvit or a placebo every day for 8 weeks.

The concentration of urolithin metabolites A, B, and C in the serum and blood cells was higher in the supplement group than in the placebo group, who presented with marginal metabolites.5 Interestingly, the number of urolithin producers increased over the time of Robuvit intake, which suggests that the gut bacteria, responsible for urolithin production can be induced by regular Robuvit supplementation (Fig. 3A).5 A statistically significant association of lower postsurgical pain scores and urolithin A-producing subjects (metabotype A)44 was detected (P < .05) in the Robuvit group. This shows a direct link between urolithin A and pain relief. A possible explanation for this observation is provided by the anti-inflammatory effects of urolithins.44

Cell culture experiments for example showed a downregulation effect of urolithin A on proinflammatory factors, such as nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-jB) and cyclooxygenase-2.45 The statistical significant association of the urolithin metabotype A and a postoperative recovery score suggests health advantages
for those patients, who are urolithin producers in response to Robuvit consumption.5 The subjects taking Robuvit showed an improvement in the health survey questionnaire, including general health, social functioning, and mental health after 4 weeks already (Fig. 7).14 General health improved by 18% compared to a deterioration of 3% in the placebo group. Social functioning improved by 17.5% with Robuvit and declined by 7.4% in the placebo group and mental health improved by 12.5% with Robuvit and only by 2.3% with placebo. Improvements were statistically significant in the supplement group compared to the placebo group.14 Supplementation with Robuvit relieves fatigue and accelerates recovery from temporary hepatic dysfunction. In an early registry study, the possible virtues of Robuvit for liver health contributions were investigated in individuals presenting with moderate functional alcoholic hepatic failure, characterized by decreased albumin plasma levels.7 Study participants were divided into two comparable groups, 1 with 23 participants, being supplemented with 300 mg Robuvit per day and a second group with 21 participants as control group. Study participants in both groups were investigated
over a period of 12 weeks. The results revealed that the group supplemented with Robuvit had significantly lower values of total bilirubin and aspartate transaminase (AST) than the control group, after 6 and 12 weeks.7 Daily intake of Robuvit led to a faster and significantly higher increase of albumin levels than in the control group. After 12 weeks, fatigue almost disappeared in the Robuvit group with only 17% of the subjects suffering from fatigue, while it was still present in 43% of the subjects in the control group. The authors concluded that supplementation with Robuvit is valuable for liver health and functionality.7

Another investigation with 61 participants presenting with temporarymoderate hepatic injury, related to acetaminophen-, antibiotics- or excessive alcohol ingestion exemplifies
regenerative properties of Robuvit.19 Following a supplementation with 200–300 mg (3 mg/[kg.day]) Robuvit per day for 4 weeks, the average total bilirubin values decreased significantly.19 After 12 weeks of supplementation with Robuvit, a significant improvement and normal values were reached. Liver enzyme markers alanine transaminase, AST, gamma-glutamyl transferase, C-reactive protein, and erythrocyte sedimentation rate, as well as oxidative stress significantly improved compared to the control group.19

Robuvit improves renal function and fatigue in kidney insufficiency. Supplementation with 300 mg Robuvit per day over a 4-week period was found to improve kidney function in 57 individuals, presenting with temporary kidney dysfunction.10 Study participants were recruited and distributed to either the Robuvit supplementation group or the control group. Fatigue, which was present in all patients at baseline, persisted only in 6.6% of the subjects supplemented with Robuvit, whereas it persisted in 46.6% of the control patients. Study participants with microalbuminuria, who took Robuvit, achieved full normalization of albumin levels.10 This shows a significant improvement of the renal function with Robuvit.
Robuvit decreases mononucleosis-related fatigue. Mononucleosis represents an infectious disease, predominantly caused by the Epstein-Barr virus, which is commonly transferred by kissing. The symptoms of the infection normally encompass fever, sore throat, lymphadenopathy, and general fatigue.46 Signs and symptoms such as a fever and
sore throat usually lessen within a couple of weeks, but fatigue, enlarged lymph nodes, and a swollen spleen may last for a few weeks or even months. A group of 50 individuals
with mononucleosis were assigned to either the group receiving standard management of the infection, or to another group, receiving same treatment, supplemented with Robuvit 300 mg daily.12 Both groups were monitored over a period of 4 weeks. The group, additionally supplemented with Robuvit, showed a statistically significantly improved
recovery than the group receiving standard treatment for mononucleosis, particularly regarding the decrease of fatigue.12

Robuvit improves fatigue due to mild heart failure. Heart failure is a chronic condition, in which the heart does not pump blood as it should. Therefore, transportation of oxygen- and nutrient-rich blood to tissues is reduced. Consequently, affected individuals are rapidly exhausted, even when walking just short distances. To help classify heart failure and guide treatment, ejection fraction is used as an important measurement of the pumping capacity of the heart. Ejection fraction means the percentage of the blood that fills the ventricle and is pumped out with each beat. For an investigation of Robuvit’s potential benefits on mild heart failure, 40 study participants with mild, stable heart failure were recruited.26 The study participants were either assigned to the group continuing their medications as before or another group supplemented with Robuvit 300 mg/day in addition to their medications over an observational time period of 12 weeks. The ejection fraction in study participants who took Robuvit significantly improved by 7.2% in only 8 weeks, while it did not significantly improve in the control group.26 This effect could be explained by the ability of Robuvit to stimulate protein production and skeletal muscle growth. Walking distance on a treadmill was significantly extended in the Robuvit-supplemented group compared with the control group. Finally, fatigue, one of the hallmarks of heart failure, was significantly reduced by Robuvit intake.

The score of the modified fatigue impact scale was reduced by more than 54% within 8 weeks in the Robuvit group and remained stable in the control group. The study authors of
this pilot study concluded that Robuvit may aid individuals who present with mild heart failure.26 Robuvit improves fatigue in postflu convalescence.

Ippolito et al. revealed the efficacy of supplementation with Robuvit for improving fatigue in medical convalescence, after the postdisease period (3 days without disease) subsequent to an influenza infection.11 Thirty-eight subjects were included and followed-up for 3 weeks. Eighteen subjects received Robuvit 300 mg/day and 20 subjects served as controls. At baseline, both groups had comparable symptom severity. Compared with controls, subjects supplemented with Robuvit showed significant improvement as early as day 10, and, after 3 weeks, for more symptoms such as weakness, recovery after effort, and alterations in attention and sleep patterns. In addition, performance, heart rate, and
oxygen saturation were significantly improved with Robuvit compared with the control group.11

Robuvit is beneficial for individuals suffering from posttraumatic stress disorder by decreasing fatigue. Supplementation with Robuvit is ascribed to benefit individuals, who suffered a posttraumatic stress disorder (PTSD),17 a disorder characterized by failure to recover after experiencing or witnessing a terrifying event. The condition may last months or years, with triggers that can bring back memories of the trauma accompanied by intense emotional and physical reactions. Symptoms may include nightmares or flashbacks, avoidance of situations that bring back the trauma, heightened reactivity to stimuli, anxiety, or depressed mood. A clinical trial investigated earthquake sufferers in Italy, who subsequently to the catastrophe experienced a PTSD.17 In all included cases, a well-defined initial traumatic event with multiple fractures occurred, requiring surgery and at least 3 weeks of hospitalization.

Volunteering catastrophe survivors of both genders, who agreed to participate in a clinical trial, were supplemented with Robuvit 300 mg/day, whereas a parallel control group received same medical attention, yet in absence of Robuvit supplementation. The study outcome showed that 4 weeks supplementation with Robuvit significantly lowered signs and symptoms of PTSD and decreased the subject’s suffering from recurrent memories and nightmares.17 Robuvit 8 WEICHMANN ET AL. improved sleep, relieved hypervigilance, intense emotional distress, and emotional numbness and greatly reduced fatigue, enabling people to better cope with PTSD.17

Robuvit supplementation in subjects with burnout syndrome. An investigation of the effect of Robuvit in 108 participants suffering from burnout, who had significant chronic fatigue, was conducted to identify benefits for individuals living under particularly stressful circumstances.18 Forty-two surgeons in training and 66 particularly severely challenged professionals were recruited to identify virtues of Robuvit supplementation. Robuvit intake at the dose of 300 mg/day for 4 weeks significantly improved the burnout symptoms in comparison with the control group.18 The symptoms assessed by a questionnaire included coping with problems, feeling positive, being satisfied, and feeling happy at work. In addition, study participants who supplemented with Robuvit experienced a high and significant relieve of emotional drainage, fatigue, level of intolerance, and strain from interactions. The author’s conclusions mention a better control of stress management due to fatigue relief.18

Greater endurance in sports

Robuvit improves triathlon performance. The contribution of Robuvit on physical expenditure during sport activities was investigated in a controlled trial with 54 recreational sports people of both genders, aged 30–40 years, performing in a triathlon.6 One group of 27 participants supplemented with Robuvit 300 mg daily, another 27 comparative individuals were assigned to the control group.

Before comparative performances, both groups trained repeatedly together. A significant performance increase after 2 weeks training was identified in subjects with Robuvit supplementation, compared to the corresponding control group, who presented with performance increase as well due to training (Fig. 8).6 In addition, this study evaluated the postperformance cramps a day after the triathlon and localized the pain of participants by means of a visual analog rating scale.6 Both muscle pain and cramping were described to be significantly lower in the Robuvit supplemented group than in the control group. An interesting observation is that lactate dehydrogenase and unconjugated bilirubin were significantly increased after performance in the control group, while the Robuvit supplemented group presented with no significant alterations of blood hemolysis markers.6 These observed effects could be explained by the accelerated mitophagy and the increase in muscle mass. Being facilitated by Robuvit, these mechanisms are suggested to represent the basic contributions for greater physical expenditure in sport activities.

Amelioration of erectile function

Two different studies suggest a positive effect of Robuvit in sexual function.22,24 In a study with 80 patients suffering from chronic fatigue syndrome, 38 of them were supplemented with 300 mg Robuvit per day for 6 months and 42 served as controls.22 Already after 4 weeks of supplementation, the participants stated a significant improvement of sexual and relational life by 66%, whereas the control group showed a slight decrease.22 Another study on the effects of Robuvit supplementation was conducted, including 40 men between 50 and 65 years who complained of decreased general vigor.24 The subjects reported a significant decrease in erectile dysfunction of 38% after 4 weeks, compared to the control men, who stated a decrease of only 10%.24 The underlying mechanism of action for this effect was not elucidated yet, but the general increase of energy due to mitophagy, muscle mass increase, and enhanced ribosomal protein expression could explain the ameliorated erectile function. More clinical investigations are needed to confirm the results, but the current data suggest an enhancement of sexual function after Robuvit supplementation.

AUTHOR DISCLOSURE STATEMENT
F.W., F.A., and C.B. are scientific employees of Horphag Research LTD.

FUNDING INFORMATION
The authors received no specific funding for this work.

REFERENCES
1. Mosedale JR, Puech JL.: Wood maturation of distilled beverages. Trends Food Sci Technol 1998;9:95–101.
2. Singleton V, Draper DE: Wood chips and wine treatment; the nature of aqueous alcohol extracts. Am J Enol Vitic 1961;12:152–158.
3. Callejo´n RM, Torija MJ, Mas A, Morales ML, Troncoso AM: Changes of volatile compounds in wine vinegars during their elaboration in barrels made from different woods. Food Chem 2010;120:561–571.
4. Garcia-Estevez I, Escribano-Bailon MT, Rivas-Gonzalo JC, Alcalde-Eon C: Development of a fractionation method for the detection and identification of oak ellagitannins in red wines. Anal Chim Acta 2010;660:171–176.
5. Volpp L, Ferianec V, Jezovicova M, Durackova Z, Scherf-Clavel O, Hogger P: Constituents and metabolites of a French Oak Wood Extract (Robuvit((R))) in serum and blood cell samples of women undergoing hysterectomy. Front Pharmacol 2020;11:74.
6. Vinciguerra MG, Belcaro G, Cacchio M: Robuvit(R) and endurance in triathlon: Improvements in training performance, recovery and oxidative stress. Minerva Cardioangiol 2015;63: 403–409.
7. Pellegrini L, Belcaro G, Dugall M, Corsi M, Luzzi R, Hosoi M: Supplementary management of functional, temporary alcoholic hepatic damage with Robuvit(R) (French oak wood extract). Minerva Gastroenterol Dietol 2016;62:245–252.
8. Orsza´ghova´ Z, Waczulı´kova´ I, Burki C, Rohdewald P, Dˇurackova´: An effect of oak-wood extract (Robuvit) on energy state of healthy adults—A pilot study. Phytother Res 2015;29: 1219–1224.
9. Natella F, Leoni G, Maldini M, et al.: Absorption, metabolism, and effects at transcriptome level of a standardized French oak wood extract, robuvit, in healthy volunteers: Pilot study. J agric food chem 2014;62:443–453.
10. Ledda A, Belcaro G, Feragalli B, et al.: Temporary kidney dysfunction: Robuvit(R) supplementation in initial, transient kidney insufficiency and micro-macro albuminuria. Panminerva Med 2018;60:60–64.
11. Ippolito E, Belcaro G, Luzzi R, et al.: Robuvit(R): Improvement
of fatigue in medical convalescence. J Sports Med Phys Fitness
2018;58:678–683.
12. Hu S, Belcaro G, Ledda A, et al.: Mononucleosis-related fatigue: Supplementary management with Robuvit(R). Minerva Pediatr 2018;70:425–429.
13. Horvathova M, Orszaghova Z, Laubertova L, et al.: Effect of the French oak wood extract Robuvit on markers of oxidative stress and activity of antioxidant enzymes in healthy volunteers: A pilot study. Oxid med cell longev 2014;2014:639868.
14. Ferianec V, Fulop M, Jezovicova M, et al.: The oak-wood extract Robuvit((R)) improves recovery and oxidative stress after hysterectomy: A randomized, double-blind, placebo-controlled pilot study. Nutrients 2020;12:913.
15. Deakova Z, Orszaghova Z, Andrezalova L, et al.: Influence of oak wood polyphenols on cysteine, homocysteine and glutathione total levels and PON1 activities in human adult volunteers— A pilot study. Gen Physiol Biophys 2015;34:73–80.
16. Belcaro G, Saggino A, Cornelli U, et al.: Improvement in mood, oxidative stress, fatigue, and insomnia following supplementary management with Robuvit(R). J Neurosurg Sci 2018;62:423–427.
17. Belcaro G, Luzzi R, Hosoi M, Dugall M, Cesarone MR: Supplementation with Robuvit(R) in post-traumatic stress disorders associated to high oxidative stress. Minerva Med 2018;
109:363–368.
18. Belcaro G, Hosoi M, Feragalli B, Luzzi R, Dugall M: Supplementation with Robuvit(R) in subjects with burnout associated to high oxidative stress. Minerva Med 2018;109:211–217.
19. Belcaro G, Gizzi G, Hu S, et al.: Robuvit(R) (French oak wood extract) in the management of functional, temporary hepatic damage. A registry, pilot study. Minerva Med 2014;105:41–50.
20. Belcaro G, Dugall M, Hu S, Ledda A, Ippolito E: French Oak Wood (Quercus robur) extract (Robuvit) in primary lymphedema: A supplement, pilot, registry evaluation. Int J Angiol 2014; 24:47–54.

Walmart Canada more than triples order of Tesla Semi Trucks

0

 

Walmart Canada is more than tripling its reservations of 18-wheeler Tesla Semi trucks as it drives towards its commitment to alternative power.

Walmart Canada is now reserving a total of 130 Tesla Semi-trucks, making it one of the largest reservations of electrified trucks in the country. The move comes on the heels of Walmart Canada announcing a major $3.5 billion investment over the next five years aimed to generate significant growth in the business and is aligned with  Walmarts global goal to target zero emissions by 2040 announced at Climate Week earlier this month

The $3.5 billion investment will impact every aspect of the business leading to a faster e-commerce experience, two new distribution centres to speed up the flow of products, re-invented and “smarter” stores, an enhanced omni experience and modern digital tools to ensure associates can best serve customers.

Walmart Canada has built a best-in-class supply chain and is continuing to put sustainability at the forefront of its business operations, finding new and innovative ways to reduce its carbon footprint while continuing to focus on safety and delivering value to its customers. Walmart Canada is committed to converting 20 per cent of Walmart’s fleet to electric power by the end of 2022, as part of its broader goal to power its fleet using 100 per cent alternative power by 2028.

Tripling our reservation of Tesla Semi trucks is part of our ongoing effort to innovate the business and prioritize sustainability,” said John Bayliss, Senior Vice-president, Logistics and Supply Chain, Walmart Canada. “By converting 20 per cent of our fleet to electric vehicles by the end of 2022 and committing to alternative power for all fleet vehicles by 2028, we are putting safety, innovation and sustainability at the forefront of our logistics network.”

According to Tesla, the Semi will deliver a better experience for truck drivers, while increasing safety and significantly reducing the cost of cargo transport. “We are tremendously excited to equip our drivers with this next generation equipment. The safety and smart elements in the design are at the heart of our smart transportation ambition which will use technology and data to lower our operating costs and improve safety for associates,” said Francis Lalonde, Vice President, Transportation, Walmart Canada. The company cites the following sustainability and safety features as key highlights on the new Tesla Semi electric trucks:

  • Tesla Semi consumes less than two kilowatt-hours of energy per mile at Gross Vehicle Weight (GVW) and highway speed, significantly reducing operating costs per mile compared to diesel.
  • 500 miles range allows a driver to go to their destination and back without recharging (500 mile range at maximum weight at highway speed)
  • Capable of 0-60 mph in 20 seconds with a full 80,000-pound load and can climb 5 per cent grades at a steady 65 mph (compared to 45mph for the same grade in a diesel truck)
  • Regenerative braking technology recovers 98 percent of kinetic energy to the battery
  • Surrounding vehicle cameras and sensors aid object detection and minimize blind spots, automatically alerting the driver to safety hazards and obstacles
  • Additional driver safety features including Automatic Emergency Braking, Automatic Lane Keeping, Lane Departure Warning

The ability to travel 500 miles per charge is in line with Walmart Canada’s general fleet system, which consists mainly of single day round trips – allowing for the ability to convert from diesel at a faster pace. The enhanced driver safety features also offer a significant opportunity for the company to continue to address this critical issue.

Increasing the sustainability of its operations:

  • The new Surrey and Vaughan distribution centres will be zero waste facilities when they open
  • Converting all material handling equipment towards lithium ion or hydrogen technology
  • Confirming its commitment to having a 100 percent alternatively powered fleet by 2028
  • Walmart Inc. recently announced it is doubling down on addressing the growing climate crisis by targeting zero emissions across the company’s global operations by 2040.
  • Walmart and the Walmart Foundation are also committing to help protect, manage or restore at least 50 million acres of land and one million square miles of ocean by 2030 to help combat the cascading loss of nature threatening the planet.

ADP Canada National Employment Report

0

 

Total Canada Nonfarm Payroll Employment1:     -231,200

Industry Snapshot:

– Goods Producing:

  • Manufacturing     -17,900
  • Construction     -45,400
  • Natural Resources and Mining     -1,700

– Service Providing:

  • Trade/Transportation and Utilities     -62,600
  • Information     -3,100
  • Finance/Real Estate     -5,900
  • Professional/Business Services     -17,500
    – Professional/Technical     2,200
    – Management of Companies     -1,200
    – Administrative and Support     -18,600
  • Education & Health Care     -11,400
    – Educational Services     8,300
    – Health Care     -19,800
  • Leisure and Hospitality     -55,100
  • Other Services2     -10,600

* Sum of components may not equal total, due to rounding.

“January reported a decrease in jobs, the largest decrease since May 2020 during the lockdown period,” said Nela Richardson, chief economist, ADP. “The surge in COVID-19 cases and public health restrictions resulted in mass layoffs. Job losses were reported in every sector, led by trade, transportation and utilities; leisure and hospitality; and construction.”

The December total of jobs added was revised from -28,800 to 338,200.

10 million dollars for mental health!

0

 

The 2016-2020 major fundraising campaign of the Fondation de l’Institut universitaire en santé mentale de Montréal, “Donnez un peu, beaucoup, à la folie “, came to an end last December 31, 2020.

Surpassing the $8 million dollar set objective, it is with nearly $10 million dollars that the FIUSMM will continue to support people suffering from mental health problems, whether by developing new treatments or by supporting the recovery and reintegration of clients into the community.

Campaign Partners (CNW Group/Fondation de l’Institut universitaire en santé mentale de Montréal)

“We are proud, moved and fulfilled by the results of this second major fundraising campaign in the history of our Foundation,” explains Martin Gagnon, President of the Board of Directors of the FIUSMM. “As honorary chairs, Mr. Louis Vachon, Mr. Éric Martel and Mr. Yvon Charest formed a remarkable trio, along with the campaign cabinet, the Board of Directors and the Foundation’s Executive Director, Ms. Carole Morin.  It was a great honour to work with these exceptional leaders. Their collaboration, their great generosity and their shared desire to advance the cause have largely contributed to this success. ”

Impacts of this campaign have already made their mark in various mental health projects, in both clinical practice and research. Even if the campaign officially ended just a few weeks ago, several initiatives have already seen the light of day and they are initiatives that will have a strong positive impact in the community for many years to come.

The funds raised will concretely enable the FIUSMM to support programs for the early detection and treatment of severe mental health disorders for teenagers and young adults. The FIUSMM will also continue to support the deployment of mobile intervention and home follow-up teams. It will also contribute to the recovery and reintegration of individuals within the community, notably by increasing its offer in front-line services through the relocation and redevelopment of the Émile-Nelligan Crisis Centre. Lastly but nonetheless, the FIUSMM will continue to support the innovations of researchers at the IUSMM research center, including the Chair in Mental health & work, the Signature Bank and innovative mental health projects.

The next few years will be most inspiring as we continue the work on three innovative projects, including the improvement of front-line mental health care and the early detection and prevention of mental illness and violence in psychiatry.

To the generous donors who have enabled us to reach $10 million, thank you!

Natural Products Expo in 2021

0

 

For the past 40 years, Natural Products Expo West has gathered the natural and organic products industry each March in Anaheim to capture and propel the incredible innovation, connections and inspiration that exist within our community. We all felt the impact of not being able to gather in person in 2020, and Informa Markets’ New Hope Network was hopeful that postponing Expo West 2021 to the end of May would result in us being able to confidently convene this important community event this Spring. Unfortunately, we have now reached the incredibly difficult decision to cancel the in-person Expo West event this Spring, instead of focusing our efforts on an enhanced Expo East event in September which will serve as the platform for our community to connect in-person in 2021.

The decision to refocus our efforts on the Fall event was reached through careful consideration of current government restrictions, anticipated timelines around re-opening in California, and industry feedback. We recognize the tremendous efforts and investments that go into participating in our events, and we know prolonging this decision would have prevented our community from making informed choices on time, budget and resource allocations later in 2021, and beyond.

While we are unable to meet in-person this May, all of us at New Hope are committed to continuing serving and uniting this industry, connecting buyers and brands, and providing new environments for product discovery, networking and education. As we look ahead to brighter days in 2021, we are excited to announce an enhanced Natural Products Expo East to serve both Expo East and West customers this Fall in Philadelphia (Sept 22-25), as well as the official launch of Natural Products Expo West Virtual Week (May 24-27). We will also be convening the industry for our year-round Spark Change virtual events and are exploring other ways we can meet our community’s changing needs through small, targeted in-person events and more.

An Expanded Expo East in Philadelphia
We are enthusiastically preparing for the next time our entire industry will gather in-person at Expo East in September. Philadelphia has much to offer the natural and organic products community, notably a beautiful convention center that can accommodate our expanded presence as we bring “West to East” and migrate many of the events, brands and features we’ve historically hosted in Anaheim. Along with connecting buyers and sellers in more curated ways, Expo East will bring to life our standards-driven approach to CPG sourcing and strengthen our industry’s efforts to grow organic and regenerative agriculture, engage in climate action, and foster justice, equity, diversity and inclusion. In addition, Expo East will again be co-located with Biofach America and we look forward to continuing our longstanding partnership with the Biofach team to further support the worldwide organic movement.

Plus, Philly will give our community an easy-to-navigate city environment that caters to foodies of all types, history buffs and people who want to take advantage of Pennsylvania’s rich organic agriculture scene.

Expo West Virtual Week
Originally designed to complement the Anaheim experience with digital programming access, Expo West Virtual Week will now expand to feature virtual booths, a comprehensive sampling program, networking opportunities, curated retailer/buyer programs, and conference programming focused on product innovations and trends. If you are a buyer of natural and organic products, Expo West Virtual Week is being designed to better meet your needs, whether you’re an independent natural retailer, a large chain prioritizing natural or a buyer wanting to break into this increasingly important CPG segment.

Next steps for Expo West exhibitors
For our partners who were scheduled to exhibit or sponsor at Expo West 2021, we hope you will join us at the Expo East+ event this Fall and our New Hope sales account managers will work with each of you to determine the next steps. In the coming days, exhibitors will also receive a meeting invite to schedule time with our account managers to review Expo West 2022 exhibit space options, address questions or concerns, and receive more information on Expo West Virtual Week and our Expo East 2021 expansion plans.